Supernus Pharmaceuticals | SUPN - Cost Of Sales


Supernus Pharmaceuticals reported $49.04M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Abbott USD 5.3B 380M Mar/2026
ANI Pharmaceuticals USD 114.5M 8.38M Mar/2026
Aurora Cannabis CAD 88.61M 30.53M Dec/2025
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Canopy Growth CAD 53.08M 8.3M Dec/2025
Cara Therapeutics USD 0 0 Mar/2025
Corcept Therapeutics USD 2.88M 338K Mar/2026
Eisai JPY 52.02B 931M Mar/2026
Eli Lilly USD 3.58B 205M Mar/2026
Novo Nordisk DKK 13.6B 1.55B Mar/2026
Pacira USD 50.74M 3.89M Mar/2026
Perrigo USD 643.7M 103.7M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
Supernus Pharmaceuticals USD 49.04M 1.5M Mar/2026
United Therapeutics USD 133.4M 341.3M Mar/2026
Xeris Pharmaceuticals USD 13.66M 49K Dec/2025